Cellectar Biosciences (CLRB)
Develops targeted radiotherapeutics for cancer through a phospholipid drug conjugate platform.
Something off on this page? Send us feedback.
Develops cancer-targeted radiotherapeutics through a phospholipid drug conjugate platform, led by iopofosine for Waldenström macroglobulinemia. It is a pre-revenue, single-segment oncology developer that depends on outside capital and contractors while pursuing regulatory approval.
Develops cancer-targeted radiotherapeutics through its phospholipid drug conjugate platform, which attaches radioactive or other payloads to a phospholipid ether intended to accumulate in cancer cells. Iopofosine is the lead program for relapsed or refractory Waldenström macroglobulinemia; CLR 125 is in early clinical development for refractory triple-negative breast cancer, while CLR 225 and other PDCs remain preclinical.
Operates as a pre-revenue, single-segment oncology developer rather than a product seller. A lean internal team directs research and development alongside contract research organizations, hospitals, academic centers, isotope suppliers, and radiopharmaceutical manufacturers across the United States and internationally.
Future commercialization depends on regulatory approval, financing, and either direct sales capability or partners. Clinical execution and product supply rely on outside vendors for radioactive isotopes, manufacturing, shipping, and compliance.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| May 5, 2026 | Roth Capital | Target | Target: — | Target: $11 |
| Mar 10, 2026 | Maxim Group | Upgrade | ||
| May 14, 2025 | Maxim Group | Downgrade | ||
| Dec 11, 2024 | Oppenheimer | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $34.0M · Total debt $1.5M · Total assets $36.6M · Shareholders' equity $29.9M
- Revenue
- $0
- Operating income
- −$7.2M
- Net income
- −$6.9M
No dividends on record.
| Institutions | 40.80% | 3.26M shares | |
|---|---|---|---|
| 29 holders · as of Jun 30, 2026 | |||
| Insiders | 0.59% | 47.2K shares | |
| 4 holders · as of May 11, 2026 | |||
| Strategic holders | 9.99% | 798.4K shares | |
| 1 holder · as of Jun 5, 2026 | |||
| Other | 48.62% | 3.88M shares | |
| remainder | |||
7.99M company shares as of Aug 26, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (9.45M in the company's Sep 23, 2026 report, 7.99M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Janus Henderson Group PLCStrategic | 9.99% | 798,382 | filed Jun 5, 2026 |
Caligan Partners LPInstitution | 5.88% | 469,998 | as of Jun 30, 2026 |
Stempoint Capital LPInstitution | 4.44% | 354,938 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.10% | 327,367 | as of Jun 30, 2026 |
Silverarc Capital Management, LLCInstitution | 4.03% | 321,728 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 7, 2026 | James V. Caruso | director, officer: Chief Executive Officer | +34,720 | $2.88 |
| May 7, 2026 | Jarrod Longcor | officer: Chief Operating Officer | +34,720 | $2.88 |
| Dec 12, 2025 | John Neis | director | −198 | $3.70 |
- BeOne Medicines (ADR)
Brukinsa is the key WM BTK-inhibitor alternative.
- AbbVie
Imbruvica is an established BTK-inhibitor option in WM.
- Gilead Sciences
Trodelvy provides a mature ADC standard in TNBC.
- Johnson & Johnson
Janssen co-commercializes Imbruvica for WM treatment.
- Merck
Keytruda anchors immunotherapy-based TNBC regimens.
- Novartis (ADR)
Radioligand scale competes for nuclear-medicine capacity.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cellectar Biosciences | $2.22 | −0.45% | $17.8M | — | — | — | — |
| BeOne Medicines (ADR) | $362.78 | −1.44% | $39.33B | 5.1 | 46.0 | 6.4 | +29.6% |
| AbbVie | $264.71 | −0.19% | $468.77B | 74.8 | 17.4 | 7.3 | +10.2% |
| Gilead Sciences | $150.90 | −1.16% | $189.30B | — | 16.7 | 6.2 | +10.2% |
| Johnson & Johnson | $268.32 | −0.32% | $648.72B | 31.2 | 22.6 | 6.6 | +6.6% |
| Merck | $147.24 | −2.44% | $372.73B | 120.7 | 17.1 | 5.6 | +5.1% |
| Novartis (ADR) | $142.25 | +0.69% | $268.53B | 21.3 | 15.1 | 4.8 | +0.9% |
| Median | 31.2 | 17.2 | 6.3 | +8.4% |